NeurogesX 8-K 2008
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
November 7, 2008 (November 6, 2008)
Date of Report (date of earliest event reported)
(Exact name of Registrant as specified in its charter)
2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404
(Address of principal executive offices)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On November 6, 2008, NeurogesX, Inc. (the Company) issued a press release regarding the Companys financial results for the third quarter ended September 30, 2008 and held a teleconference to review these results and discuss corporate and clinical initiatives for the remainder of 2008 and into 2009. A copy of the press release and the script of the teleconference are filed as Exhibit 99.1 and 99.2 respectively, to this Form 8-K, the contents of which are incorporated by reference into this Item 2.02.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.